Recent studies have indicated that circulating microRNAs (miRNAs) in serum and plasma are stable and can serve as biomarkers of many human diseases. Measurement of circulating miRNAs with sufficient sensitivity and precision, however, faces some special challenges, among which proper normalization is the most critical but often an underappreciated issue. The primary aim of this study was to identify endogenous reference genes that maintain consistent levels under various conditions to serve as an internal control for quantification of serum miRNAs. We developed a strategy combining Illumina’s sequencing by synthesis (SBS) technology, reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay, literature screening and statistical analysis to screen and validate the most suitable reference genes. A combination of let-7d, let-7g and let-7i is selected as a reference for the normalization of serum miRNAs and it is statistically superior to the commonly used reference genes U6, RNU44, RNU48 and miR-16. This has important implications for proper experimental design and accurate data interpretation.
Citation: Chen X, Liang H, Guan D, Wang C, Hu X, Cui L, et al. (2013) A Combination of Let-7d, Let-7g and Let-7i Serves as a Stable Reference for Normalization of Serum microRNAs. PLoS ONE 8(11): e79652. https://doi.org/10.1371/journal.pone.0079652
Editor: Rakesh K. Srivastava, The University of Kansas Medical center, United States of America
Received: May 14, 2013; Accepted: October 3, 2013; Published: November 5, 2013
Copyright: © 2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Basic Research Program of China (973 Program) (no. 2014CB542300), the National Natural Science Foundation of China (Nos. 81101330, 31271378 and 81250044) and the Natural Science Foundation of Jiangsu Province (Nos. BK2011013 and BK2012014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
MicroRNAs (miRNAs) are small noncoding RNAs with a length of approximately 22 nucleotides that play important roles in gene regulatory networks [1-3]. Recently, we and other groups have demonstrated that miRNAs circulate in a highly stable, cell-free form in body fluids including serum [4,5], plasma , saliva , urine  and milk [9,10]. Furthermore, aberrant expression of circulating miRNAs has been detected in a wide range of pathological conditions including cancer [4-8], diabetes , acute myocardial infarction  and tissue injury . These findings suggest broad opportunities for development of circulating miRNAs as non-invasive biomarkers for molecular diagnostics and prognostics. However, when performing the experiments to quantify circulating miRNAs, variations in the amount of starting material, sample collection, RNA extraction and enzymatic efficiency may introduce potential bias and contribute to quantification errors. Given these concerns, the development of an effective normalization strategy is critical for evaluating circulating miRNAs. Among a variety of available normalization methods, normalization against a stable reference gene (or better a set of multiple stable reference genes) is currently the most accurate and suitable method for evaluation of circulating miRNAs . In contrast, other normalization methods may obscure real changes and produce artificial changes. For example, data normalization can be carried out against total RNA content, but this approach requires an accurate quantification of the isolated total RNA. Because serum and plasma are cell-free samples with very low amounts of total RNA (the concentration of total RNA purified from serum/plasma can be measured using NanoDrop spectrophotometer but is usually < 50 ng/μL) , standard methods for measurement of the RNA yield and quality are inappropriate for these types of samples. This means that normalization to total RNA is not a reliable and accurate method.
Here, we report a systematic strategy to identify and characterize the most stable reference genes for normalizing serum miRNAs in healthy people and patients with a variety of diseases. A final combination of three miRNAs, let-7d, let-7g and let-7i, was found to give highly consistent results across numerous healthy controls and patients with diseases. These miRNAs were statistically superior to the most commonly used reference genes in the quantification of serum miRNAs.
Patients and Control Subjects
Patients with pathologically confirmed, newly diagnosed, untreated cancers, inflammatory diseases or type 2 diabetes were recruited at the Jinling Hospital (Nanjing, China). Blood was also collected from healthy participants during physical examinations performed at the Jinling Hospital. Written informed consent was obtained from all patients and healthy participants prior to the study. The study protocol was approved by the ethics committee of Nanjing University. Sample sets were shown in Table 1.
|Sample set 1||Sample set 2||Sample set 3||Sample set 4|
|Variable||Patients (n=130)||Controls (n=100)||p-value||Patients (n=21)||Controls (n=35)||p-value||Patients (n=777)||Controls (n=1278)||p-value||Patients (n=84)||Controls (n=41)||p-value|
|Average age (years)||60.77±9.42||36.51±22.65||< 0.001a||63.24±7.32||60.69±8.44||0.2553a||59.29±9.96||59.19±10.10||0.8212a||60.88±8.60||58.63±9.51||0.1878a|
|Type 2 diabetes||320|
RNA Isolation, SBS Technology and RT-qPCR
Venous blood samples (~5 ml) were collected from each donor and placed in a serum separator tube. Samples were processed within one hour. Separation of the serum was accomplished by centrifugation at 800 g for 10 min at room temperature, followed by a 15-min high-speed centrifugation at 10,000 g at room temperature to completely remove the cell debris. The supernatant serum was recovered and stored at -80°C until analysis. Those serum samples with pink/red discolouration were considered to be haemolysed and were excluded.
For the Illumina’s sequencing by synthesis (SBS) technology, serum pools were created by combining 10 samples (5 mL each) and mixing vigorously. Then, total RNA was extracted from the 50 mL of pooled serum using the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Then sequencing procedure was conducted as previously described . For detailed methodology, see Method S1.
For the reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay, total RNA was extracted from 100 μL of serum with a one-step phenol/chloroform purification protocol. Quantification of serum miRNAs was then carried out using a Taqman miRNA PCR kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Primers used in this study are shown in Table S1. For detailed methodology, see Method S1.
The RT-qPCR was performed in triplicate, and each experiment was repeated several times. Data shown are presented as the mean ± SEM of at least three independent experiments. Statistical analyses were performed with SPSS 15.0 statistical software, and a p-value < 0.05 using t-test was considered statistically significant. Selection of optimal reference gene was conducted using geNorm and NormFinder as previously described [15,16]. For detailed methodology, see Method S1.
We developed a strategy combining four main steps to identify and validate the suitable set of genes for normalization of serum miRNAs (Figure 1). In step one, we employed SBS technology to screen a sample set representing a wide range of physiological and pathological conditions. Two statistical algorithms, geNorm and NormFinder, were implemented to rank gene stability and select the most stable candidates exhibiting minimal variance across different samples. The second step involved screening published literature to identify frequently used reference genes. This two-step approach to selecting candidate reference genes provided more gene information in order to find optimal reference genes with greater accuracy. In step three, the selected candidates identified in steps one and two were combined, and their stability was evaluated by RT-qPCR and analyzed by geNorm and NormFinder in serum samples from 21 cancer patients and 35 controls. The most stable reference gene identified was subsequently validated in serum samples from an additional 1278 controls, 257 cancer patients, 200 patients with inflammatory diseases and 320 patients with type 2 diabetes. Finally, we characterized the absolute concentration of the optimal reference genes identified in our primary analysis and assessed their stability in serum after various treatments. In an independent experiment, we used the optimal reference genes to normalize the levels of target miRNAs in serum samples from 84 cancer patients and 41 controls, demonstrating that the reference gene selection can have a significant influence on serum miRNA quantification.
Selection of the Most Stable Reference Genes by SBS Technology
We first screened a SBS dataset to identify stable serum miRNAs across various physiological and pathological conditions. A total of 23 pooled serum samples were analyzed, including 8 healthy male or female samples of different ages (baby boy, baby girl, young boy, young girl, middle-aged man, middle-aged woman, old man and old woman; each pool was created by combining 10 individual serum samples), 2 mixed healthy samples (middle-aged and old; each pooled from 5 male and 5 female) and 13 cancer patients (3 non-small cell lung cancer, 2 breast cancer, 2 gastric cancer, 2 esophageal cancer, 1 colorectal cancer, 1 pancreatic cancer, 1 cervical cancer and 1 hepatocellular carcinoma; each pool was created by combining 10 individual serum samples). MiRNAs were considered stable if they fulfilled the following criteria: (1) expressed in all samples; (2) highly expressed, as measured by the mean; and (3) consistently expressed, as measured by the standard deviations. According to these criteria, 25 miRNAs were selected as candidate reference genes. As shown in Figure 2A, SBS reads were converted to the log2 scale, and genes were sorted by the mean expression levels and standard deviations. Among the miRNAs detected, 25 miRNAs had high abundance (log2-transformed reads > 10) and low standard deviations (
< 1) in the dataset. The mean expression values of the selected 25 miRNAs are shown in Figure 2B.
(A) Sera from cancer patients and healthy participants were pooled separately as described above, and miRNA levels were determined using SBS technology. SBS reads were converted to the log2 scale. The average log2-transformed read of each miRNA was plotted against the standard deviation of the log2-transformed read. MiRNAs highlighted in red are those with higher abundance (log2-transformed reads > 10) and lower standard deviations (< 1) in the dataset. (B) The average expression values (SBS reads ± standard errors) of the selected miRNAs were plotted. (C) Selection of the most stable reference genes from a panel of 25 genes using geNorm. The geNorm program calculates the average expression stability value (M) for each gene. Genes with the lowest M values are considered the most stable. The least stable gene with the highest M value was automatically excluded for the next calculation round. The x-axis from left to right indicates the ranking of the reference genes according to their expression stability from the least to the most stable, and the y-axis represents the M values of the remaining reference genes. (D) Identification of the optimal number of reference genes for accurate normalization using geNorm. V is the pairwise variation (Vn/Vn+1) between two sequential normalization factors (NFn and NFn+1). The magnitude of the change in the normalization factor after the inclusion of an additional reference gene reflects the improvement that is obtained. The authors of geNorm suggest that V > 0.15 should be considered the threshold for including an extra reference gene in the assay, and the least number of genes for each V < 0.15 is selected as the optimal set of genes for normalization. (E) Selection of the most stable reference gene or gene combinations using geNorm. In this case, geNorm indicated that the combination of let-7d, let-7g and let-7i was statistically superior to other combinations or each individually. (F) Identification of the most stable reference genes using NormFinder. The NormFinder algorithm ranks the set of candidate normalization genes according to their expression stability in different groups (e.g., disease versus normal). According to this algorithm, lower stability values of the individual genes indicate greater gene stability. In this case, 23 samples were divided into two groups (12 normal controls and 11 cancer patients). Blue bars represent the stability values of the candidate genes.
The stability of the candidate reference genes was further evaluated by two different algorithms, geNorm  and NormFinder . The geNorm algorithm calculates the average expression stability (M value) of a gene by using pairwise comparisons, ranking putative reference genes according to the similarity of expression profiles across a sample set . Genes with the lowest M values are considered the most stable. The stability ranking of each candidate gene is determined by stepwise exclusion of the gene with highest M value, followed by recalculation of average expression stability for the remaining genes until the two most stable genes are found . The curve presented in Figure 2C plots the average expression stability of the 25 candidate reference genes. As shown, let-7g was the most stably expressed gene within the group, followed by let-7i and let-7d. The geNorm analysis also allows for evaluation of the suitable number of reference genes required for reliable and accurate normalization . This algorithm determines the optimal number of reference genes using a metric called V, which is the pairwise variation (Vn/Vn+1) of two sequential normalization factors (NFn/NFn+1). It is suggested that the cut-off value of 0.15 should be considered as a limit beneath which the use of additional reference genes would not be required . The results showed that the optimal number of genes for accurate normalization was three, and the combination of let-7d, let-7g and let-7i was sufficient to accurately normalize a target gene in this dataset, yielding a V value of 0.13 that is lower than the cutoff value 0.15 (Figure 2D). Indeed, the total amount of let-7d/g/i trio was optimal for normalization and was statistically superior to the combinations of two let-7 members or individual let-7 member (Figure 2E). On the other hand, NormFinder uses a solid statistical framework to estimate not only the overall expression variation of the candidate reference genes, but also the variation between subgroups (e.g., tumor versus normal) . According to this algorithm, genes with the lowest stability will be ranked highest . When the gene expression stability was estimated independently using the NormFinder software, the result was essentially the same as that from geNorm. The NormFinder algorithm selected let-7i as the optimal reference gene for normalization, followed by let-7d and let-7g (Figure 2F).
Literature-based selection of additional candidate reference genes
The three newly selected candidate reference genes were further evaluated along with several traditionally utilized reference genes, including large molecular weight RNAs (GAPDH and β-actin), small nuclear/nucleolar RNAs (snRNA/snoRNA) (U6, RNU44 and RNU48) and housekeeping miRNAs (miR-16, miR-191, miR-103 and miR-23a). GAPDH and β-actin were selected based on previous studies reporting their stable expression in tissues and cells . U6 [18-20], RNU44 [21-23], RNU48 [24,25], miR-16 , miR-191 , miR-103  and miR-23a  were selected because they are commonly utilized reference genes in analyzing tissue/cell miRNA. In addition, we focused on U6 [29,30] and miR-16 [4,31-33], which have been used as reference genes for normalization of serum miRNAs.
Development of an approach to measure the total amount of let-7d, let-7g and let-7i in a run
The RT-qPCR assay is currently the most sensitive and reliable method to determine the levels of circulating miRNAs [13,34]. However, while SBS technology is easy to assess the total amount of let-7d, let-7g and let-7i in a run, in the RT-qPCR assay one reaction just enable analysis of one miRNA. Therefore, to provide increased flexibility and decreased time and effort for determining the reference gene, an approach should be developed to simultaneously analyze multiple members of the let-7d/g/i trio. Given that the TaqMan miRNA assays can successfully discriminate each members of the let-7 family without interference (Figure S1) and that each member of the let-7d/g/i trio has approximately equal amplification efficiencies (Figure S2), we designed an approach to simultaneously measure the total amount of let-7d/g/i trio in a same RT-qPCR reaction. Briefly, let-7d, let-7g and let-7i in 5 μL of total RNA were reverse-transcribed in a single reaction using specific RT Primer pool, a mixture of stem-loop primers of let-7d, let-7g and let-7i (in the ratio of 1:1:1). Accordingly, real-time PCR was performed using TaqMan miRNA probe pool of let-7d, let-7g and let-7i (in the ratio of 1:1:1). With this approach, one reaction was sufficient to accurately quantify the total amount of let-7d/g/i trio, no matter how many individual let-7d, let-7g and let-7i were present in the samples (Table 2).
|miRNA input (attomole)||Total let-7d/g/i amount|
Validation of the stability of the selected candidate reference genes by RT-qPCR
Next, RT-qPCR assay was performed to further evaluate the expression patterns of the selected candidate reference genes in a sample set of 21 cancer patients and 35 healthy controls. As controls, we analyzed miR-20a , miR-21 [33,36,37], miR-24  and miR-25 [35,37], the levels of which have previously been shown to be significantly dysregulated in serum from cancer patients. As shown in Figure 3A, the reference genes displayed a wide range of levels, with threshold cycle (Cq) values ranging from 21 to 33, and the smallest variation was observed with let-7d/g/i. Next, the geNorm and NormFinder algorithms were used to rank the candidate reference genes according to their expression stability. Based on calculations performed with geNorm, let-7d/g/i had the most stable expression levels and thus was selected as the best combination of reference genes (Figure 3B). In contrast, miR-191, miR-103, U6, miR-16, RNU48 and RNU44, the commonly used reference genes for miRNA RT-qPCR experiments, ranked behind let-7d/g/i (Figure 3B), suggesting that they should not be considered reliable reference genes for data normalization. NormFinder confirmed the results obtained by geNorm, showing that let-7d/g/i was the most stable reference gene set, whereas miR-24 was the least stable gene (Figure 3C). The identified optimal reference gene set, let-7d/g/i, was subsequently validated in a large sample set containing 1278 healthy controls, 257 cancer patients, 200 patients with inflammatory diseases and 320 patients with type 2 diabetes. As shown in Figure 3D, the expression levels of let-7d/g/i remained constant across individuals tested, independent of the disease condition.
(A) Expression levels of candidate reference genes in serum. The expression levels of 14 candidates were measured by RT-qPCR in the sera from cancer patients (n = 21) and healthy controls (n = 35). The Cq values (median and range) of each miRNA were shown by box-and-whisker plots. Significance was calculated by t-test. (B) Identification of the optimal number of reference genes for accurate normalization using geNorm. (C) Identification of the most stable reference genes using NormFinder. (D) Expression levels of let-7d/g/i in large numbers of serum samples. The expression levels of let-7d/g/i were measured in the sera from healthy controls (n = 1278), cancer patients (n = 254), patients with inflammatory diseases (n = 200) and patients with type 2 diabetes (n = 320). The Cq values (median and range) in each group were shown by box-and-whisker plots. Significance was calculated by t-test.
Characterization of the absolute concentration of let-7d/g/i in serum
We next evaluated the linear dynamic range and sensitivity of the RT-qPCR assay for measuring let-7d/g/i. Synthetic single-stranded let-7d/g/i was serially diluted and assessed by the RT-qPCR assay. Decreasing the amount of let-7d/g/i led to a corresponding increase in the mean Cq values, with a Pearson correlation coefficient (R) of 0.992 (Figure 4A). The results demonstrated that the let-7d/g/i RT-qPCR assay has a dynamic range of at least ten orders of magnitude and is capable of detecting as few as 0.01 attomole of let-7d/g/i (equivalent to 6,000 copies). Additionally, the expression levels of let-7d/g/i in RNA samples isolated from various volumes of serum were characterized using the RT-qPCR assay. The RT-qPCR assay showed excellent linearity between the serum volume and Cq value (R = 0.9865) (Figure 4B). These results demonstrate that let-7d/g/i in as little as 10 µL of serum can be efficiently detected and reliably compared across multiple samples. By referring to the standard curve, we calculated that the absolute concentration of let-7d/g/i in serum was 271.35 ± 21.48 fmol/L.
(A) Dynamic range and sensitivity of the RT-qPCR assay for measuring let-7d/g/i (n = 5). Synthetic single-stranded let-7d/g/i ranging from 0.01 attomole (0.0033 attomole each, equivalent to 6×103 copies in total) to 10 pmol (3.3 pmol each) were serially diluted over ten orders of magnitude and were assessed by the RT-qPCR assay. The resulting Cq values were plotted versus the amount of input let-7d/g/i to generate a standard curve. An assay using water instead of RNA for reverse-transcription was included as a negative control. (B) Correlation of serum volume to the Cq values (n = 5). Total RNA was extracted from different volumes of serum ranging from 10 µL to 400 µL. The levels of serum let-7d/g/i were assessed by RT-qPCR. The resulting Cq values were plotted versus the serum volume used for RNA extraction. An assay using water instead of RNA for reverse-transcription was included as a negative control. (C) Stability of let-7d/g/i in serum after extended storage (n = 5). Serum samples were equally divided and stored at room temperature, 4°C, -20°C or -80°C for 1, 2, 3, 7, 14 or 30 days. For each time point, total RNA was isolated and let-7d/g/i was measured by RT-qPCR assay. Storage at room temperature for 30 days yielded no apparent increase in Cq values. (D) Instability of other RNAs in serum (n = 5). Serum samples were equally divided and stored at room temperature for 1 to 24 h. For each time point, total RNA was isolated, and the levels of some large molecular weight RNA (β-actin, GAPDH and 28S rRNA) and snRNA/snoRNA (U6, RNU44, RNU48, SNORD24, SNORD38B, SNORD43, SNORA66 and SNORA74A) were measured by RT-qPCR. Storage at room temperature for 24 h resulted in an apparent increase of Cq values for these RNAs. (E) Stability of let-7d/g/i in serum after RNase digestion (n = 5). Serum samples were treated with 10 U/ml RNase A and 400 U/ml RNase T1 for 4 h at 37°C. After the treatment, the RNA was extracted from the serum, and the levels of let-7d/g/i were assessed by RT-qPCR. (F) Instability of other RNAs in serum after RNase digestion (n = 5). Serum samples were treated with 10 U/ml RNase A and 400 U/ml RNase T1 for 1, 2 or 4 h at 37°C. After the treatment, the RNA was extracted and the levels of the indicated RNAs were assessed by RT-qPCR assay. (G and H) Stability of let-7d/g/i under acidic or alkaline conditions (n = 5). Serum samples were incubated for 1 h under acidic (pH 2) or alkaline (pH 12) conditions. The levels of let-7d/g/i were assessed by RT-qPCR. (I) Stability of let-7d/g/i in serum following re-freezing and re-thawing of the samples (n = 6). Serum samples were subjected to eight freeze-thaw cycles.
The stability of let-7d/g/i in serum
To be used as a suitable reference gene in clinical tests, let-7d/g/i must be stable in serum for reasonable periods of time and preferably resistant to some harsh conditions, thereby allowing for routine processing of clinical samples. We first studied the stability of let-7d/g/i in sera stored for extended periods of time at different temperatures. No significant differences in Cq values were observed between the different storage time points (long-term versus short-term) or storage conditions (sub-zero versus high temperature) (Figure 4C). In contrast, large molecular weight RNA and snRNA/snoRNA were quickly degraded within 24 hours of storage at room temperature (Figure 4D). Furthermore, when serum samples were treated with RNase serum let-7d/g/i had considerable resistance to enzymatic cleavage (Figure 4E), but synthetic let-7d/g/i and other RNAs rapidly degraded (Figure 4F). The results suggest that RNase in serum can rapidly degrade large molecular weight RNA and snRNA/snoRNA but has much less of an effect on serum let-7d/g/i. Moreover, we found that the levels of let-7d/g/i in serum did not change substantially in acidic or alkaline conditions (Figure 4, G and H) and were barely affected by eight cycles of re-freezing and re-thawing of serum samples (Figure 4I).
Quantification of serum miRNAs is significantly influenced by different normalization approaches
To demonstrate that our proposed method is the best approach to control for variations in RNA recovery and amplification efficiency, we test the accuracy of let-7d/g/i as a reference gene by using exogeneous miRNA (spiked-in miRNA) as target. A 22-nt artificial miRNA which showed no sequence homology with endogenous miRNAs was spiked into three groups of serum samples (in the ratio of 1:2:4) after the addition of denaturing solution. Then, total RNA was isolated and the relative levels of artificial miRNA were calculated by normalization with serum volume, let-7d/g/i, U6 or miR-191, individually. Although all normalization approaches showed gradually elevation of artificial miRNA in groups with more added artificial miRNA, normalization with let-7d/g/i produced the most consistent results compared with the initial input (Figure 5A). The results suggest that normalization to let-7d/g/i is a superior normalization method as it corrects experimental variations better than existing methods and achieves accurate identification where others do not. Furthermore, we selected endogenous miR-25, miR-214, miR-223 and miR-483-5p as targets because they are well-characterized oncogenic miRNAs that have been shown to be elevated in sera from cancer patients [5,35,37]. We assessed the relative levels of these miRNAs in the sera of cancer patients and healthy controls by normalizing to serum volume, let-7d/g/i, U6 or miR-191, respectively. Only those miRNAs with a mean fold change > 2 and p-value < 0.05 were considered to be significantly upregulated. Normalization with let-7d/g/i revealed significant upregulation of miR-25, miR-214, miR-223 and miR-483-5p in serum from cancer patients compared with normal controls (Figure 5B). The direction of the fold change after normalization to serum volume was in agreement with the normalization with let-7d/g/i, but only miR-223 was shown to be significantly higher in serum from cancer patients (Figure 5B). However, normalization with U6 or miR-191 revealed no significant differences in miR-25, miR-214, miR-223 or miR-483-5p levels in serum from cancer patients versus controls (Figure 5B). The results further demonstrate that different normalization strategies significantly influence the consequence: the use of stable genes for normalization will improve sensitivity and reproducibility, whereas the choice of unstable reference genes can lead to inaccurate results.
(A) Serum samples from healthy controls, ulcerative colitis patients and colon cancer patients were divided into three groups (n =5 in each group). After the initial denaturation steps, 1, 2 and 4 attomole of synthetic artificial miRNA (5’-GUGGAUUCCGUCUCGUUAG-3’) were spiked into 100 μL of serum of each group (1 attomole for control group, 2 attomole for ulcerative colitis group and 4 attomole for colon cancer group). After isolation of total RNA, the levels of artificial miRNA were assessed by RT-qPCR assay and were normalized to serum volume, let-7d/g/i, U6 or miR-191, respectively. Relative levels were calculated using the 2-△△Cq method and were shown by dot plots. Significance was calculated by t-test. (B) Expression levels of miR-25, miR-214, miR-223 and miR-483-5p were measured in serum from cancer patients (n = 84) and healthy controls (n = 41) by RT-qPCR and were normalized to serum volume, let-7d/g/i, U6 or miR-191. Relative levels were calculated using the 2-△△Cq method and are presented as mean fold changes ± standard errors. Significance was calculated by t-test.
Ideal endogenous reference genes should do the following: (1) exhibit stable expression across all samples and experimental conditions; (2) have comparable abundance to the targets of interest; and (3) share similar properties as the targets, such as stability, size and purification procedure . To date, the selection of reference genes to normalize circulating miRNAs is still rather empirical, and no reference genes that fulfill the above-mentioned criteria are currently available. Because the yield of total RNA from small-volume serum samples (i.e., 100 µL) was below the limit of accurate quantification by spectrophotometry, the inclusion of an endogenous reference gene is indispensable for adjusting for technical variations in the RNA recovery procedure. Bias in sample collection, storage and processing also affects the accuracy and reliability of the quantitative analysis of circulating miRNAs. As such, systematic selection and validation of suitable reference genes for quantification of circulating miRNAs is needed, especially in diseases such as cancer where the global expression of circulating miRNAs may be dramatically altered in the context of rapid physiological and pathological changes.
Although several genes are traditionally utilized as endogenous reference genes for tissue/cell miRNAs, it is not reasonable to use these genes to normalize circulating miRNA levels because they are not miRNAs and may not be representative of the miRNA fraction. In addition, the efficiency of their extraction, reverse transcription and PCR amplification may differ from that of circulating miRNAs. Therefore, these genes may not be an ideal choice. Indeed, our study clearly demonstrates that these genes varied greatly in serum and were unstable even after short-term storage (Figure 4).
In previous studies, synthetic non-human (e.g., C. elegans) miRNAs have been used as spike-in controls to normalize the levels of circulating miRNAs . These molecules can provide a reference for normalization of the technical variability in RNA extraction. However, spike-in controls do not correct for variability in sample collection and therefore cannot improve assay precision. Indeed, it has been reported that the spiked exogenous C. elegans miRNAs, including cel-miR-39, cel-miR-54 and cel-miR-238, did not significantly improve assay precision . Therefore, spike-in controls are also not an ideal choice.
The high stability of circulating miRNAs in human body fluids raises important and intriguing questions regarding the mechanism by which miRNAs are protected from digestion. Two models have been proposed to account for this: (1) circulating miRNAs are protected by packaging inside microvesicles , and (2) circulating miRNAs are protected via association with proteins such as Argonaute2 (Ago2), high-density lipoprotein and nucleophosmin 1 (NPM1) . From this point of view, circulating miRNAs represent a unique class of molecules that differ from other types of RNAs in serum. Therefore, circulating miRNAs themselves may be the sole suitable reference genes for normalization of circulating miRNAs, as they share similar properties, such as stability and purification procedure. However, the reference circulating miRNAs must be carefully selected and systematically validated to avoid inaccurate normalization. For example, studies have been performed using circulating miR-16 as a reference gene under the assumption that its levels are stable across experimental conditions [4,31-33]. However, a systematic evaluation of miR-16 as a reference gene for normalization has not been published. In fact, it has been reported that endogenous miR-16 was a poor normalizing factor . By employing SBS technology and RT-qPCR assay, we selected and validated the combination of let-7d, let-7g and let-7i as the best reference gene for normalization of serum miRNAs (Figure 2 and 3). Furthermore, we systematically demonstrate that normalization to let-7d/g/i is a superior normalization method as it corrects experimental variations better than existing methods and achieves accurate identification where others do not (Figure 5). However, the reference genes identified currently were different from those found in previous studies [14,42], although these studies also used similar methods and algorithms (e.g., geNorm and NormFinder) to select suitable reference genes. We think that this inconsistency may be due to the differences in study design, disease type, sample size and methodology. For example, the aim of this study is to identify the common reference gene for normalization of serum miRNAs; thus, we investigate serum miRNAs in a large sample set including more than 2000 serum samples across healthy controls and patients with a variety of different diseases. In contrast, the previous studies focused on a specific disease and therefore investigated miRNAs only in a small patient cohort. Furthermore, we screened the levels of all miRNAs in serum by SBS technology, while the previous studies only assessed limited miRNAs. Nevertheless, all of these studies demonstrated that reference gene choice for circulating miRNA analysis has a great effect on the study outcome, and that it is necessary to choose a suitable reference for reliable normalization of circulating miRNAs.
In summary, our findings constitute the first report describing the rigorous identification and validation of suitable reference genes for normalization of miRNAs in serum. This has important implications for proper experimental design and accurate data interpretation.
Discrimination ability of the RT-qPCR assay for individual members of the let-7 family. Because the let-7 family members differ by only a single or a few nucleotides, it should be ensured that the RT-qPCR assays can discriminate each members of the let-7 family without interference. To this end, 10 attomole of synthetic single-stranded let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g and let-7i were individually assessed by the RT-qPCR assay; each assay was examined against a targeted let-7 member and the remaining let-7 species. Relative detection rate was calculated based on the Cq values between perfectly matched and mismatched targets, assuming 100% efficiency for the perfect match. The results showed that RT-qPCR assays targeting the matched let-7 species produced Cq values much lower than those for mismatched; mismatched targets would contribute < 1% background signal to the assay of the targeted let-7 species.
Standard curves for let-7d, let-7g and let-7i. The standard curves were generated by RT-qPCR amplifying with 104, 103, 102, 10, 1 or 0.1 attomole of synthetic single-stranded let-7d, let-7g or let-7i, respectively (n = 5). The resulting Cq values were plotted against the logarithm of the input amount of let-7d, let-7g and let-7i. The slope and intercept for let-7d, let-7g or let-7i were about −3.4 and 27.8, indicating approximately equal amplification efficiency.
Detailed methodology for RNA isolation, SBS technology, RT-qPCR and data analysis.
Conceived and designed the experiments: CYZ KZ JZ. Performed the experiments: XC HL DG. Analyzed the data: SC. Contributed reagents/materials/analysis tools: CW XH LC CZ. Wrote the manuscript: CYZ KZ JZ.
- 1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297. doi:10.1016/S0092-8674(04)00045-5. PubMed: 14744438.
- 2. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350-355. doi:10.1038/nature02871. PubMed: 15372042.
- 3. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531. doi:10.1038/nrg1379. PubMed: 15211354.
- 4. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP et al. (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675. doi:10.1111/j.1365-2141.2008.07077.x. PubMed: 18318758.
- 5. Chen X, Ba Y, Ma L, Cai X, Yin Y et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006. doi:10.1038/cr.2008.282. PubMed: 18766170.
- 6. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518. PubMed: 18663219.
- 7. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA et al. (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15: 5473-5477. doi:10.1158/1078-0432.CCR-09-0736. PubMed: 19706812.
- 8. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I et al. (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28: 655-661. doi:10.1016/j.urolonc.2009.01.027. PubMed: 19375957.
- 9. Kosaka N, Izumi H, Sekine K, Ochiya T (2010) microRNA as a new immune-regulatory agent in breast milk. Silence. p. 1: 7.
- 10. Chen X, Gao C, Li H, Huang L, Sun Q et al. (2010) Identification and characterization of microRNAs in raw milk during different periods of lactation, commercial fluid, and powdered milk products. Cell Res 20: 1128-1137. doi:10.1038/cr.2010.80. PubMed: 20548333.
- 11. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y et al. (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659-666. PubMed: 20159880.
- 12. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A et al. (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106: 4402-4407. PubMed: 19246379.
- 13. Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50: 298-301. PubMed: 20146939.
- 14. Zhu HT, Dong QZ, Wang G, Zhou HJ, Ren N et al. (2012) Identification of suitable reference genes for qRT-PCR analysis of circulating microRNAs in hepatitis B virus-infected patients. Mol Biotechnol 50: 49-56. doi:10.1007/s12033-011-9414-6. PubMed: 21567136.
- 15. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034. PubMed: 12184808.
- 16. Andersen CL, Jensen JL, Ørntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245-5250. doi:10.1158/0008-5472.CAN-04-0496. PubMed: 15289330.
- 17. Suzuki T, Higgins PJ, Crawford DR (2000) Control selection for RNA quantitation. BioTechniques 29: 332-337. PubMed: 10948434.
- 18. Choong ML, Yang HH, McNiece I (2007) MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol 35: 551-564. PubMed: 17379065.
- 19. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67: 8433-8438. PubMed: 17823410.
- 20. Wang XH, Tang S, Le SY, Lu R, Rader JS et al. (2008) Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth. PLOS ONE 3: e2557. PubMed: 18596939.
- 21. Yousef GM, Youssef YM, White NMA, Grigull J, Krizova A et al. (2011) Accurate Molecular Classification of Kidney Cancer Subtypes Using MicroRNA Signature. Eur Urol 59: 721-730. PubMed: 21272993.
- 22. Williams AE, Larner-Svensson H, Perry MM, Campbell GA, Herrick SE et al. (2009) MicroRNA Expression Profiling in Mild Asthmatic Human Airways and Effect of Corticosteroid Therapy. PLOS ONE 4: e5889. PubMed: 19521514.
- 23. Anglicheau D, Sharma VK, Ding R, Hummel A, Snopkowski C et al. (2009) MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 106: 5330-5335. PubMed: 19289845.
- 24. Clapé C, Fritz V, Henriquet C, Apparailly F, Fernandez PL et al. (2009) miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice. PLOS ONE 4: e7542. PubMed: 19855844.
- 25. Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Sakurai D et al. (2011) Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum Genet 56: 595-601. PubMed: 21753766.
- 26. Zhi F, Chen X, Wang S, Xia X, Shi Y et al. (2010) The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 46: 1640-1649. PubMed: 20219352.
- 27. Peltier HJ, Latham GJ (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14: 844-852. PubMed: 18375788.
- 28. Shen Y, Li Y, Ye F, Wang F, Wan X et al. (2011) Identification of miR-23a as a novel microRNA normalizer for relative quantification in human uterine cervical tissues. Exp Mol Med 43: 358-366. PubMed: 21519184.
- 29. Ng EK, Chong WW, Jin H, Lam EK, Shin VY et al. (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58: 1375-1381. doi:10.1136/gut.2008.167817. PubMed: 19201770.
- 30. Ai J, Zhang R, Li Y, Pu J, Lu Y et al. (2010) Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 391: 73-77. PubMed: 19896465.
- 31. Huang Z, Huang D, Ni S, Peng Z, Sheng W et al. (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 118-126. doi:10.1002/ijc.25007. PubMed: 19876917.
- 32. Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW et al. (2010) Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 16: 360-364. doi:10.1111/j.1601-0825.2009.01646.x. PubMed: 20233326.
- 33. Wang J, Chen J, Chang P, LeBlanc A, Li D et al. (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer. Prev Res (Phila) 2: 807-813. doi:10.1158/1940-6207.CAPR-09-0094.
- 34. Hastings ML, Palma J, Duelli DM (2012) Sensitive PCR-based quantitation of cell-free circulating microRNAs. Methods 58: 144-150. PubMed: 22884953.
- 35. Chen X, Hu Z, Wang W, Ba Y, Ma L et al. (2012) Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130: 1620-1628. PubMed: 21557218.
- 36. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM et al. (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55-59. PubMed: 18954897.
- 37. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY et al. (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70: 9798-9807. PubMed: 21098710.
- 38. Suzuki T, Higgins PJ, Crawford DR (2000) Control selection for RNA quantitation. BioTechniques 29: 332-337. PubMed: 10948434.
- 39. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57: 833-840. doi:10.1373/clinchem.2010.157198. PubMed: 21487102.
- 40. Zhang Y, Liu D, Chen X, Li J, Li L et al. (2010) Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 39: 133-144. doi:10.1016/j.molcel.2010.06.010. PubMed: 20603081.
- 41. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108: 5003-5008. PubMed: 21383194.
- 42. Song J, Bai Z, Han W, Zhang J, Meng H et al. (2012) Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 57: 897-904. PubMed: 22198701.